P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE

Ngā tūemi rite

• P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
  mā: Myrthe van Dijk, me ētahi atu.
  I whakaputaina: (2023-08-01)
• P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
  mā: M. J. van Dijk, me ētahi atu.
  I whakaputaina: (2022-06-01)
• 5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
  mā: M.J. van Dijk, me ētahi atu.
  I whakaputaina: (2023-04-01)
• Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease
  mā: Myrthe J. vanDijk, me ētahi atu.
  I whakaputaina: (2024-06-01)
• AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes
  mā: Minke A.E. Rab, me ētahi atu.
  I whakaputaina: (2020-01-01)